Skip to main content

Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial.

  • 2020
  • Food & Function 11(1)
    • Song Lin
    • Shanliang Zhao
    • Jiahong Liu
    • Jianwen Zhang
    • Chao Zhang
    • Haibo Hao
    • Yuxia Sun
    • Jing Cai
    • Yang Yang
    • Yan Ma
    • Yuanyuan Li
    • Jinyu Wang
    • A. Ma

Abstract

Anti-tuberculosis (TB) drugs can induce a series of gastrointestinal adverse events, which can seriously affect patients' quality of life and may lead to treatment failure. Studies have shown that probiotics treatments can improve antibiotic-induced gastrointestinal symptoms. In this randomized, open-label, dose-response clinical trial, we investigated the preventive effects of Lactobacillus casei on anti-TB-induced gastrointestinal adverse events. In total, 429 adult patients who underwent intensive-phase anti-TB therapy were included and randomly assigned to consume one bottle of L. casei of per day (low-dose group, n = 142), two bottles of L. casei per day (high-dose group, n = 143), or no intervention (control group, n = 144) for 2 months. Each bottle of L. casei contained 10 billion colony-forming units of live L. casei. Patients' daily gastrointestinal symptoms were recorded during the intervention period. After 2 months of L. casei consumption, 397 patients had completed the intervention. Both the high and low dose L. casei groups (37.6% and 29.4%, respectively) had lower incidences of anti-TB-associated total gastrointestinal adverse events than the control group (50.0%). The high and low dose L. casei groups (3.5 d and 5.8 d, respectively) also had shorter duration anti-TB-associated adverse gastrointestinal symptoms than the control group (6.2 d). Regarding individual symptoms, the higher L. casei dose resulted in a lower incidence of vomiting and appetite loss. Similar dose-dependent protective effects of L. casei were observed regarding the duration of vomiting and appetite loss. These findings indicated that daily L. casei consumption prevented anti-TB-associated gastrointestinal adverse events. This trial was registered at the Chinese Clinical Trial Register (ChiCTR-IOR-17013210).

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lacticaseibacillus caseiReduced Appetite Loss IncidenceBeneficial
Moderate
Lacticaseibacillus caseiReduced Duration of Anti-TB-associated Gastrointestinal SymptomsBeneficial
Moderate
Lacticaseibacillus caseiReduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lacticaseibacillus caseiReduced Vomiting DurationBeneficial
Moderate
Lacticaseibacillus caseiReduced Vomiting IncidenceBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Appetite Loss IncidenceBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Duration of Gastrointestinal SymptomsBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Vomiting DurationBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Vomiting IncidenceBeneficial
Moderate
Lactobacillus caseiReduced Duration of Gastrointestinal SymptomsBeneficial
Moderate
Lactobacillus caseiReduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lactobacillus caseiReduced Vomiting DurationBeneficial
Moderate
Lactobacillus caseiReduced Vomiting IncidenceBeneficial
Moderate
Lactobacillus casei R0215Reduced Appetite Loss IncidenceBeneficial
Moderate
Lactobacillus casei R0215Reduced Duration of Anti-TB-associated Gastrointestinal SymptomsBeneficial
Moderate
Lactobacillus casei R0215Reduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lactobacillus casei R0215Reduced Vomiting IncidenceBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Appetite Loss IncidenceBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Duration of Appetite LossBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Duration of VomitingBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Vomiting IncidenceBeneficial
Moderate
Lactobacillus casei subsp. caseiReduced Appetite Loss IncidenceBeneficial
Moderate
Lactobacillus casei subsp. caseiReduced Incidence of Gastrointestinal Adverse EventsBeneficial
Moderate
Lactobacillus casei subsp. caseiReduced Vomiting IncidenceBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.